6 results match your criteria: "Research Centre of Inflammation[Affiliation]"
Sci Rep
November 2020
INSERM, Research Centre of Inflammation, Laboratoire d'excellence Inflamex, BP 416, Paris, France.
The conditions used to describe the presence of an immune disease are often represented by interaction graphs. These informative, but intricate structures are susceptible to perturbations at different levels. The mode in which that perturbation occurs is still of utmost importance in areas such as cell reprogramming and therapeutics models.
View Article and Find Full Text PDFEMBO Mol Med
June 2019
INSERM, UMR1149, Team «Gut Inflammation», Research Centre of Inflammation, Paris, France
Clin Gastroenterol Hepatol
April 2019
Intestinal Inflammation Team, Research Centre of Inflammation, UMR1149, INSERM, Paris, France; Université Paris Diderot/Université Sorbonne Paris Cité, Paris, France; Laboratory of Excellence, Labex INFLAMEX, Université Sorbonne Paris Cité, Paris, France; Hôpital Beaujon, Assistance Publique Hôpitaux de Paris, Clichy la Garenne, France. Electronic address:
Background & Aims: Acute severe ulcerative colitis (ASUC) is a life-threatening condition managed with intravenous steroids followed by infliximab, cyclosporine, or colectomy (for patients with steroid resistance). There are no biomarkers to identify patients most likely to respond to therapy; ineffective medical treatment can delay colectomy and increase morbidity and mortality. We aimed to identify biomarkers of response to medical therapy for patients with ASUC.
View Article and Find Full Text PDFFront Physiol
July 2018
Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France.
Mucus is a major component of the intestinal barrier involved both in the protection of the host and the fitness of commensals of the gut. is consumed world-wide in fermented dairy products and is also recognized as a probiotic, as its consumption is associated with improved lactose digestion. We determined the overall effect of on the mucus by evaluating its ability to adhere, degrade, modify, or induce the production of mucus and/or mucins.
View Article and Find Full Text PDFBackgrounds And Aims: The effect of cigarette smoking [CS] is ambivalent since smoking improves ulcerative colitis [UC] while it worsens Crohn's disease [CD]. Although this clinical relationship between inflammatory bowel disease [IBD] and tobacco is well established, only a few experimental works have investigated the effect of smoking on the colonic barrier homeostasis focusing on xenobiotic detoxification genes.
Methods: A comprehensive and integrated comparative analysis of the global xenobiotic detoxification capacity of the normal colonic mucosa of healthy smokers [n = 8] and non-smokers [n = 9] versus the non-affected colonic mucosa of UC patients [n = 19] was performed by quantitative real-time polymerase chain reaction [qRT PCR].
Br J Cancer
July 2014
Department of Oncology, Rigshospitalet, DK 2100 Copenhagen, Denmark.
Background: Bleomycin-etoposid-cisplatin (BEP) chemotherapy is curative in most patients with disseminated germ cell cancer (GCC) but also associated with toxic actions and dysfunction in non-targeted tissues. We investigated changes in muscle function during BEP and the safety and efficacy of resistance training to modulate these changes.
Methods: Thirty GCC patients were randomly assigned to resistance training (resistance training group (INT), n=15) or usual care (CON, n=15) during 9 weeks of BEP therapy.